Pascal Finetti

List of Publications by Year
in descending order

67 papers	4,069 citations	218677 26 h-index	118850 62 g-index
68 all docs	68 docs citations	68 times ranked	7315 citing authors

#	Article	IF	Citations
1	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137.	5.9	10
2	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	5.2	6
3	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
4	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death and Disease, 2022, 13, 96.	6.3	13
5	RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute, 2022, 114, 1046-1047.	6.3	9
6	Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. Cancers, 2022, 14, 932.	3.7	5
7	CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response. Cancers, 2022, 14, 1306.	3.7	3
8	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. Cancers, 2022, 14, 2275.	3.7	0
9	Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate. Molecular Cancer Therapeutics, 2022, 21, 1227-1235.	4.1	13
10	CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. Cancers, 2022, 14, 3356.	3.7	2
11	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	11
12	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2314-2325.	7.0	10
13	EFA6B regulates a stop signal for collective invasion in breast cancer. Nature Communications, 2021, 12, 2198.	12.8	2
14	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	8.2	24
15	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers, 2021, 13, 2807.	3.7	19
16	WEE1 Dependency and Pejorative Prognostic Value in Triple–Negative Breast Cancer. Advanced Science, 2021, 8, e2101030.	11.2	8
17	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology, 2021, 15, 2752-2765.	4.6	19
18	LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Communications Biology, 2021, 4, 987.	4.4	6

#	Article	IF	Citations
19	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	4.6	22
20	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. In Vivo, 2020, 34, 177-184.	1.3	10
21	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	4.6	23
22	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancerâ€"Letter. Clinical Cancer Research, 2020, 26, 5539-5539.	7.0	0
23	Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. Cancers, 2020, 12, 3058.	3.7	9
24	Neoplasticâ€"Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Molecular Cancer Research, 2020, 18, 1889-1902.	3.4	11
25	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. Cancers, 2020, 12, 2470.	3.7	14
26	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
27	The therapeutic response of ER+/HER2â€ breast cancers differs according to the molecular Basal or Luminal subtype. Npj Breast Cancer, 2020, 6, 8.	5.2	27
28	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, 2020, 12, 689.	3.7	14
29	Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions. Cancers, 2020, 12, 1730.	3.7	26
30	Inflammatory breast cancer cells are characterized by abrogated TGFÎ²1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment, 2020, 180, 385-395.	2.5	18
31	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. Cancers, 2019, 11, 1158.	3.7	6
32	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clinical Epigenetics, 2019, 11, 141.	4.1	11
33	A genomeâ€wide <scp>RNA</scp> i screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Molecular Medicine, 2019, 11, e9930.	6.9	27
34	PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. OncoImmunology, 2019, 8, e1655362.	4.6	39
35	PARP1 expression in soft tissue sarcomas is a poorâ€prognosis factor and a new potential therapeutic target. Molecular Oncology, 2019, 13, 1577-1588.	4.6	15
36	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. British Journal of Cancer, 2019, 120, 931-940.	6.4	13

#	ARTICLE	IF	CITATIONS
37	Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight, 2019, 4, .	5.0	31
38	â€œWnt/Î²-Catenin in GISTâ€â€"Letter. Molecular Cancer Therapeutics, 2018, 17, 327-328.	4.1	4
39	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, 2018, 9, 33762-33777.	1.8	17
40	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. British Journal of Cancer, 2018, 119, 1383-1391.	6.4	54
41	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/Î²-Catenin Signaling. Stem Cell Reports, 2018, 11, 1040-1050.	4.8	18
42	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology, 2017, 6, e1278100.	4.6	65
43	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. Cell Reports, 2017, 18, 2256-2268.	6.4	111
44	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 2017, 6, e1253654.	4.6	146
45	A stemness-related ZEB1â€"MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	30.7	131
46	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia, 2017, 19, 564-573.	5.3	25
47	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomasâ€"Letter. Molecular Cancer Therapeutics, 2017, 16, 2324-2324.	4.1	2
48	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine, 2017, 15, 170.	5.5	64
49	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. Developmental Cell, 2016, 37, 311-325.	7.0	63
50	Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219.	1.8	69
51	Decreased expression of ABAT and STC2 hallmarks ERâ€positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, 2015, 9, 1218-1233.	4.6	64
52	PDL1 expression is an independent prognostic factor in localized GIST. OncoImmunology, 2015, 4, e1002729.	4.6	75
53	<i>H19</i>non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget, 2015, 6, 29209-29223.	1.8	193
54	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 2014, 9, e104302.	2.5	43

#	Article	IF	Citations
55	The Functional Landscape of Hsp27 Reveals New Cellular Processes such as DNA Repair and Alternative Splicing and Proposes Novel Anticancer Targets. Molecular and Cellular Proteomics, 2014, 13, 3585-3601.	3.8	65
56	EFA6B Antagonizes Breast Cancer. Cancer Research, 2014, 74, 5493-5506.	0.9	25
57	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Letters, 2014, 355, 70-75.	7.2	44
58	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	7.0	130
59	Difference in Therapeutic Response Between Basal and Nonbasal Triple–Negative Breast Cancers. Oncologist, 2013, 18, 1060-1061.	3.7	3
60	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. PLoS ONE, 2012, 7, e37943.	2.5	34
61	Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, 2011, 10, 86.	19.2	46
62	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, 2011, 6, e16950.	2.5	57
63	Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, 2011, 6, e27656.	2.5	143
64	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Research, 2009, 69, 1302-1313.	0.9	1,067
65	How basal are triple–negative breast cancers?. International Journal of Cancer, 2008, 123, 236-240.	5.1	384
66	Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, 2008, 68, 767-776.	0.9	105
67	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Research, 2006, 66, 4636-4644.	0.9	273